Abstract
Over the last years a number of reports have described elevated numbers of regulatory T (Treg) cells inside of tumors, in close proximity of the tumor, draining lymph nodes and also in peripheral blood of patients with solid tumors and hematologic malignancies. There is increasing evidence that Treg cells can migrate into tumors and suppress effective anti-tumor responses in the tumor microenvironment, thus contributing to the prosperity and growth of human tumors. In addition, several mechanisms have been described how conversion of conventional CD4+ T cells into Treg cells can occur in the context of human tumors, yet little is known about the molecular and cellular features responsible for the increase and maintenance of elevated levels of Treg cells in cancer. Recent studies now have elucidated how Treg cells mediate regulatory activity in the tumor microenvironment and enhanced our understanding of the underlying molecular mechanisms. Targeting Treg cells therefore provides an attractive therapeutic strategy to potentially influence the suppressed immune response in tumor patients thereby altering and supporting anti-tumor therapy.
Keywords: Regulatory T cells, tumor immunology, FOXP3
Current Pharmaceutical Design
Title: Regulatory T Cells: Major Players in the Tumor Microenvironment
Volume: 15 Issue: 16
Author(s): Marc Beyer and Joachim L. Schultze
Affiliation:
Keywords: Regulatory T cells, tumor immunology, FOXP3
Abstract: Over the last years a number of reports have described elevated numbers of regulatory T (Treg) cells inside of tumors, in close proximity of the tumor, draining lymph nodes and also in peripheral blood of patients with solid tumors and hematologic malignancies. There is increasing evidence that Treg cells can migrate into tumors and suppress effective anti-tumor responses in the tumor microenvironment, thus contributing to the prosperity and growth of human tumors. In addition, several mechanisms have been described how conversion of conventional CD4+ T cells into Treg cells can occur in the context of human tumors, yet little is known about the molecular and cellular features responsible for the increase and maintenance of elevated levels of Treg cells in cancer. Recent studies now have elucidated how Treg cells mediate regulatory activity in the tumor microenvironment and enhanced our understanding of the underlying molecular mechanisms. Targeting Treg cells therefore provides an attractive therapeutic strategy to potentially influence the suppressed immune response in tumor patients thereby altering and supporting anti-tumor therapy.
Export Options
About this article
Cite this article as:
Beyer Marc and Schultze L. Joachim, Regulatory T Cells: Major Players in the Tumor Microenvironment, Current Pharmaceutical Design 2009; 15 (16) . https://dx.doi.org/10.2174/138161209788453211
DOI https://dx.doi.org/10.2174/138161209788453211 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Thalidomide Chemotherapy-Induced Peripheral Neuropathy: Actual Status and New Perspectives with Thalidomide Analogues Derivatives
Mini-Reviews in Medicinal Chemistry Iron Supplementation Therapy in End-Stage Renal Disease Patients on Maintenance Hemodialysis
Cardiovascular & Hematological Disorders-Drug Targets An Update on the Xenograft and Mouse Models Suitable for Investigating New Therapeutic Compounds for the Treatment of B-Cell Malignancies
Current Pharmaceutical Design Epigenetic Lesions in Malignant Melanoma
Current Pharmaceutical Biotechnology Inhibitors of Lactate Dehydrogenase Isoforms and their Therapeutic Potentials
Current Medicinal Chemistry Recent Advances in the Use of Metallic Nanoparticles with Antitumoral Action - Review
Current Medicinal Chemistry MDM2-p53 Interaction in Paediatric Solid Tumours: Preclinical Rationale, Biomarkers and Resistance
Current Drug Targets Progress of HDAC Inhibitor Panobinostat in the Treatment of Cancer
Current Drug Targets HSP90 Inhibitors: Current Development and Potential in Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Adhesion Molecules and Kinases Involved in γ δ T Cells Migratory Pathways:Implications for Viral and Autoimmune Diseases
Current Medicinal Chemistry Genetic Predisposition to Neonatal Tumors
Current Pediatric Reviews Marizomib, A Potent Second Generation Proteasome Inhibitor from Natural Origin
Anti-Cancer Agents in Medicinal Chemistry Secondary Neoplasms in Children Treated for Cancer
Current Pediatric Reviews Depression has a Strong Relationship to Alterations in the Immune, Endocrine and Neural System
Current Psychiatry Reviews Targeting the Process of Farynesylation for Therapy of Hematologic Malignancies
Current Molecular Medicine Metastatic Cell Dormancy and Re-activation: An Overview on Series of Molecular Events Critical for Cancer Relapse
Anti-Cancer Agents in Medicinal Chemistry The Coordinated Role of CYP450 Enzymes and P-gp in Determining Cancer Resistance to Chemotherapy
Current Drug Metabolism Expression and Function of the Leukocyte Integrins in Organ Transplant Rejection
Current Medicinal Chemistry The Tumor Stroma as Mediator of Drug Resistance - A Potential Target to Improve Cancer Therapy?
Current Pharmaceutical Biotechnology Emerging Treatments in Acute Lymphoblastic Leukemia
Current Cancer Drug Targets